Non-IPF ILD exhibited three FVCpp trajectory clusters with annual absolute changes of –0.84%, +2.10%, and –6.30%, corresponding to 5-year terminal-outcome–free proportions of 82.0%, 73.1%, and 64.5%.
Trevi Therapeutics leverages Haduvio's dual mechanism to target IPF-related chronic cough. Click here to read why TRVI stock ...
Key Points Interested in Trevi Therapeutics, Inc.? Here are five stocks we like better. Trevi launched two trials for ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...
SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results